Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Esomeprazole for GERD in neonates
NCT00427635Phase 3Completed
- Sponsor
- AstraZeneca
- Start
- Oct 2006
- Modality
- Small Molecules
- Countries
- 3
01
Overview
Phase 3, randomised, double-blind trial in gastroesophageal reflux disease (GERD) comparing Esomeprazole with Placebo (2 arms). Primary endpoint: Normalized Number of GERD Events Observed From Video and Cardiorespiratory Monitoring at 14 days. Started Oct 2006; status: completed.
02
Drugs
esomeprazole
03
Conditions
gastroesophageal reflux disease (GERD)
Beyond the preview
Go deeper on NCT00427635.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00427635.